Clinical Trial Update: A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema [Phase 3]

View source ↗

Summary

A Phase 3 study comparing the efficacy and safety of brolucizumab versus aflibercept in diabetic macular edema has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• BEOVU (BROLUCIZUMAB)
• EYLEA (Aflibercept)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetic Macular Edema | Phase 3 | Status: COMPLETED | Results posted: 2024-01-05